Compositions for treating cognitive disorders

Abstract

Disclosed herein is a pharmaceutical composition comprising a cholinesterase inhibitor and compound of the following formula: The composition is effective for treating cognitive disorders, and methods of treating such disorders using the composition are also disclosed.

1 . A pharmaceutical composition comprising a pharmaceutically effective cholinesterase inhibitor and a compound of Formula I: 
       
         
           
           
               
               
           
         
         wherein X is CH 2  or CH 2 —CH 2 , 
         A is aryl, or is heteroaryl having 0, 1, 2, or 3 heteroatoms selected from the group consisting of N, S, and O, 
         wherein A has 0, 1, 2, or 3 substituents each comprising 0 to 8 carbon atoms, 0 to 3 oxygen atoms, 0 to 3 halogen atoms, 0 to 2 nitrogen atoms, 0 to 2 sulfur atoms, and 0 to 24 hydrogen atoms. 
       
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein A is selected from the group consisting of pyridinyl, thienyl, furyl, quinolinyl, methylphenyl, and biphenyl. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein A is unsubstituted. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the compound of Formula I is selected from the group consisting of 
       
         
           
           
               
               
           
         
       
       and enantiomers and pharmaceutically acceptable salts thereof. 
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the cholinesterase inhibitor is selected from the group consisting of donepezil, galantamine, and rivastigmine. 
     
     
         6 . A method of treating a cognitive disorder, the method comprising administering to a human in need of such a treatment the pharmaceutical composition of  claim 5 . 
     
     
         7 . The method of  claim 6 , wherein the cognitive disorder is selected from the group consisting of an agnosia, an amnesia, an aphasia, an apraxia, a delirium, a dementia, and a learning disorder. 
     
     
         8 . A method of treating a cognitive disorder, the method comprising administering to a patient in need of such a treatment a first composition comprising a pharmaceutically effective cholinesterase inhibitor and a second composition comprising compound of Formula I: 
       
         
           
           
               
               
           
         
         wherein X is CH 2  or CH 2 —CH 2 , 
         A is aryl, or is heteroaryl having 0, 1, 2, or 3 heteroatoms selected from the group consisting of N, S, and O, 
         wherein A has 0, 1, 2, or 3 substituents each comprising 0 to 8 carbon atoms, 0 to 3 oxygen atoms, 0 to 3 halogen atoms, 0 to 2 nitrogen atoms, 0 to 2 sulfur atoms, and 0 to 24 hydrogen atoms. 
       
     
     
         9 . The method of  claim 8 , wherein A is selected from the group consisting of pyridinyl, thienyl, furyl, quinolinyl, methylphenyl, and biphenyl. 
     
     
         10 . The method of  claim 9 , wherein A is unsubstituted. 
     
     
         11 . The method of  claim 8 , wherein the compound of Formula I is selected from the group consisting of 
       
         
           
           
               
               
           
         
       
       and enantiomers and pharmaceutically acceptable salts thereof. 
     
     
         12 . The method of  claim 11 , wherein the cholinesterase inhibitor is selected from the group consisting of donepezil, galantamine, and rivastigmine. 
     
     
         13 . The method of  claim 12 , wherein the cognitive disorder is selected from the group consisting of an agnosia, an amnesia, an aphasia, an apraxia, a delirium, a dementia, and a learning disorder. 
     
     
         14 . A method of treating dementia, the method comprising administering to a patient in need of such treatment a pharmaceutical composition comprising
 a) a pharmaceutically effective cholinesterase inhibitor selected from the group consisting of donepezil, galantamine, and rivastigmine; and   b) a compound selected from the group consisting of   
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable salts thereof.